The pet cancer therapeutics include chemotherapy drugs, targeted therapies, combination therapies, and immunotherapy vaccines, which are commonly recommended by the veterinary doctors. The drugs are mostly recommended to treat various conditions such as lymphoma, mast cell tumors, fibrosarcoma, hemangiosarcoma, and others. Currently, a wide range of formulations are available in the global market for the treatment of pet cancers, which can be administered in the form of tablets, injections or can be applied topically. Thus, the large variety of treatment options has made it easy for the pets to receive effective cancer treatment suitable to curb the condition.
Market Dynamics
The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2017, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.
Key features of the study:
- This report provides in-depth analysis of pet cancer therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global pet cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Aratana Therapeutics, Inc., AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Rhizen Pharmaceuticals SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, and Zoetis
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global pet cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market
Detailed Segmentation:
- Global Pet Cancer Therapeutics Market, By Therapy Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- Global Pet Cancer Therapeutics Market, By Pet Type:
- Global Pet Cancer Therapeutics Market, By Mode of Administration:
- Global Pet Cancer Therapeutics Market, By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- Global Pet Cancer Therapeutics Market, By Geography:
- North America
- By Therapy Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- By Pet Type:
- By Mode of Administration:
- By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- By Country:
- Latin America
- By Therapy Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- By Pet Type:
- By Mode of Administration:
- By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Therapy Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- By Pet Type:
- By Mode of Administration:
- By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Therapy Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- By Pet Type:
- By Mode of Administration:
- By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Therapy Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- By Pet Type:
- By Mode of Administration:
- By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Therapy Type:
- Chemotherapy
- Targeted Therapy
- Combination Therapy
- Immunotherapy
- By Pet Type:
- By Mode of Administration:
- By Application:
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary and Squamous Cell Cancer
- Others
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Aratana Therapeutics, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- AB Science
- Boehringer Ingelheim International GmbH
- Zenoaq
- Morphogenesis, Inc.
- VetDC, Inc.
- Karyopharm Therapeutics, Inc.
- Rhizen Pharmaceutical SA
- Regeneus Ltd.
- Oasmia Pharmaceuticals AB
- Zoetis
“*” marked represents similar segmentation in other categories in the respective section.
